Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis

AIMS: Medical and non-medical switching strategies have been adopted in Europe in the last few years. We aimed to investigate persistence on treatment with a SB5 Adalimumab (SB5) biosimilar after switching from Adalimumab (ADA) originator among patients with inflammatory rheumatic musculoskeletal di...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruni, Cosimo, Gentileschi, Stefano, Pacini, Giovanni, Bardelli, Marco, Tofani, Lorenzo, Bartoli, Francesca, Baldi, Caterina, Cometi, Laura, Fiori, Ginevra, Nacci, Francesca, Cantarini, Luca, Guiducci, Serena, Moggi-Pignone, Alberto, Frediani, Bruno, Matucci-Cerinic, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
The Role of Biosimilars in the Management of Rheumatic Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804457/
https://www.ncbi.nlm.nih.gov/pubmed/35116080
http://dx.doi.org/10.1177/1759720X211033679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804457/
https://www.ncbi.nlm.nih.gov/pubmed/35116080
http://dx.doi.org/10.1177/1759720X211033679

Ejemplares similares